Two Sigma Investments LP Has $3.21 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Two Sigma Investments LP trimmed its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 22.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,974 shares of the company's stock after selling 17,218 shares during the quarter. Two Sigma Investments LP owned 0.11% of Janux Therapeutics worth $3,211,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares during the period. Meeder Asset Management Inc. bought a new stake in Janux Therapeutics during the 4th quarter worth about $159,000. Tower Research Capital LLC TRC increased its stake in shares of Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after purchasing an additional 3,436 shares during the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of Janux Therapeutics during the 4th quarter worth about $221,000. Finally, Chicago Capital LLC acquired a new position in shares of Janux Therapeutics during the 4th quarter worth about $230,000. Institutional investors own 75.39% of the company's stock.

Analyst Upgrades and Downgrades

JANX has been the subject of a number of recent research reports. Scotiabank cut their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush reaffirmed an "outperform" rating and issued a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $95.25.

Insider Buying and Selling

In other Janux Therapeutics news, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the purchase, the director now directly owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. This trade represents a 3.67% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at $2,464,170. This trade represents a 3.90% decrease in their position. The disclosure for this sale can be found here. 8.10% of the stock is owned by insiders.

Janux Therapeutics Stock Up 1.7%

JANX stock traded up $0.42 during trading on Tuesday, hitting $25.43. The company had a trading volume of 947,628 shares, compared to its average volume of 878,239. The firm has a market capitalization of $1.50 billion, a P/E ratio of -21.73 and a beta of 3.24. Janux Therapeutics, Inc. has a 52-week low of $22.48 and a 52-week high of $71.71. The company has a 50 day simple moving average of $27.18 and a 200-day simple moving average of $38.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.